Long-term efficacy of lebrikizumab in treating head, neck and face involvement in patients with moderate-to-severe atopic dermatitis
In brief
Lebrikizumab preserved at least 75% head-and-neck improvement in 95% at 3 years
Among patients who responded to lebrikizumab by week 16, 94.8% still had at least 75% improvement in head, neck, and face eczema after 3 years of treatment every 4 weeks. This post hoc analysis also found sustained responses in patients with prior biologic exposure and those with skin of color, but the long-term results apply to early responders, not all treated patients.
- Journal
- The Journal of dermatological treatment (Q1)
- Published
- 19 October 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Raj Chovatiya, Marjolein de Bruin-Weller, Andrew Alexis, Chesahna Kindred, Mona Shahriari, Jill Waibel, et al.
- PMID
- 42895209
- DOI
- 10.1080/09546634.2026.2713286
Why clinicians should know about it
- Picked for Dermatology (paper of the day, 20 October 2026): Durable 3‑year efficacy in head, neck, face AD
- Picked for Immunology and Allergy (paper of the day, 20 October 2026): Durable long-term efficacy in head, neck, face AD
Abstract
OBJECTIVES: Head, neck, and face (HNF) atopic dermatitis (AD) substantially impairs quality of life, yet long-term biologic efficacy data in HNF areas remain limited. METHODS: This post hoc analysis evaluates HNF efficacy of lebrikizumab across phase 3 trials (ADvocate 1&2, ADjoin) and targeted populations (ADmirable, ADapt) in adolescents (≥12 years, ≥40 kg) and adults with moderate-to-severe AD. Outcomes included HN EASI sub-scores and Face Investigator's Global Assessment (F-IGA). RESULTS: Lebrikizumab 250 mg Q4W provided durable efficacy through 3 years among week 16 responders. At week 152, 94.8%, 82.9%, and 85.3% maintained HN EASI 75, 90, and 100 responses, respectively.Stable response (maintaining ≥80% of attended visits) through week 152 was observed in 88.8% (HN EASI 75), 80.0% (HN EASI 90), and 74.0% (HN EASI 100) of patients. Additionally, 93.8% achieved absolute HN EASI ≤1 and 69.2% achieved HN EASI = 0 at week 152 in week 16 responders. In ADmirable (skin of color), 61% of Lebri-treated patients achieved F-IGA 0 at week 24. In ADapt (prior dupilumab exposure), 55% achieved F-IGA 0 at week 24. CONCLUSIONS: Lebrikizumab provided durable, stable long-term HNF efficacy across diverse populations, including systemic-naive patients and those with prior biologic exposure.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.